Trellis Vitality review
Lab-gated, flagship unpriced
A biomarker-led longevity clinic with a named pharmacy and a genuinely cheap flat-rate GLP-1 line — that will not tell you what its flagship NAD+ protocol costs.
Our verdict
Trellis is two things at once. Its GLP-1 line is one of the most honestly structured on our board: one flat price at every dose, $150/mo semaglutide and $199/mo tirzepatide, from a named medical group and a named compounding pharmacy. Its longevity line — the thing the company is actually built around — publishes no price anywhere we could reach, and leans on outcome statistics that carry no source. A clinic that quotes what a competitor's infusion costs on its own NAD+ page, while omitting its own figure, is asking you to start an intake before you can compare. Worth considering for the GLP-1 line; ask for the NAD+ price in writing before you commit to anything else.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. This never affects our rankings or verdicts. How we make money.
At a glance
- Category
- longevity telehealth
- Access
- Semaglutide $150/mo, tirzepatide $199/mo — same price at every dose, less on 3- or 6-month plans; 50 states
- Medications
- Compounded semaglutide · Compounded tirzepatide
- Insurance
- Cash-pay, no insurance
- Visit
- Quiz intake / Async intake
- Availability
- All 50 states
- LegitScript
- Certified
- Updated
- August 2026
Popular alternative
Enhance MD
Physician-supervised NAD⁺ under lab-guided oversight
Check Enhance MD availability →What it is
A virtual longevity clinic organized around at-home lab testing and a 90-day biomarker re-test rather than a product catalog. Its self-described flagship is subcutaneous NAD+; it also offers glutathione, tesamorelin, a Lipo-MIC/B12 shot and a compounded GLP-1 line.
How it works
You begin with a free online Vitality Assessment; a licensed clinician reviews the intake and labs and prescribes only where clinically appropriate, with a re-test at 90 days meant to demonstrate whether anything moved. The designated medical group is Arora Health & Aesthetics, LLC, with Dr. Sean Arora named as medical director. Prescriptions are fulfilled by VialsRX, a state-licensed compounding pharmacy in Houston, Texas. Intake runs on an externally hosted funnel. Trellis states availability in all 50 states and displays a LegitScript certification. It is also one of the very few providers in this category to publish an llms.txt, which sets out its medical group, pharmacy and compounding disclosures in plain machine-readable text — a transparency gesture we would like to see more of.
Pricing transparency
Split, and the split is the problem. The GLP-1 line is priced clearly and well: the same rate at every dosage, with semaglutide at $150/mo month-to-month, $140 on a three-month plan and $133 on six, and tirzepatide at $199/$189/$179 on the same terms. Flat-at-every-dose pricing is genuinely consumer-friendly and rarer than it should be. Nothing else on the site carries a price. The NAD+ page — for the protocol Trellis calls its flagship — quotes a single dollar figure and it belongs to somebody else: "$200–500 per clinic infusion," the cost of the alternative it is arguing against. Its own rate appears nowhere on the product page, in the intake funnel, or anywhere else we could reach without starting a visit. The tesamorelin and glutathione pages publish no figure at all.
Branded vs compounded
All compounded, and Trellis states plainly that compounded medications are not FDA-approved as finished products. The GLP-1 line is compounded semaglutide and tirzepatide. The longevity line is subcutaneous NAD+, glutathione, tesamorelin and a lipotropic Lipo-MIC/B12 injection. On the evidence: injected NAD+ has no controlled human outcome trials, and the randomized support belongs to the oral NR and NMN precursors, where what was demonstrated is a raised blood NAD+ level rather than a clinical outcome — a distinction Trellis's own blog actually handles carefully, which makes the unsourced homepage statistics more frustrating rather than less. Tesamorelin is the one growth-hormone-axis peptide here with an FDA-approved reference product (Egrifta, for HIV-associated lipodystrophy), so its evidence base is better than sermorelin's, though not for general longevity use. Injected glutathione has essentially no controlled human outcome data.
Pros and watch-outs
What we like
- Names both sides of the care chain — Arora Health & Aesthetics under Dr. Sean Arora, and VialsRX as the dispensing pharmacy
- GLP-1 pricing is flat at every dose, so titrating up does not raise your bill
- Genuinely cheap GLP-1 rates: $150/mo semaglutide and $199/mo tirzepatide month-to-month
- Lab-gated model with an at-home baseline and a 90-day biomarker re-test
- Publishes an llms.txt disclosing its medical group, pharmacy and compounding status
- Its blog handles the NAD+ versus NR/NMN evidence question more carefully than most sellers
Watch-outs
- No price is published for NAD+, its own flagship protocol — nor for tesamorelin or glutathione
- The only figure on the NAD+ page is a competitor's infusion cost, which invites a comparison the reader cannot complete
- "92% of patients see significant biomarker improvements within 90 days" appears with no study, sample size or methodology
- "$4,000 average patient savings per year" and "3.4 weeks average patient time saved" are unsourced in the same way
- The four named patient testimonials on the homepage are the same four quotes repeated three times in the carousel
- Shares its medical group with The Edit and its pharmacy with AurenRx, both also on this board
Best for
Buyers who want a flat GLP-1 price at every dose from a named pharmacy, or who specifically want a longevity protocol gated behind real lab work and are willing to ask for the cost before starting.
Who should look elsewhere
Anyone comparison-shopping NAD+ on price, or anyone who wants published outcome claims to come with a citation attached.
The evidence behind what Trellis Vitality prescribes
We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.
- NAD+ precursors (NR and NMN): what the human trials actually show
They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.
- Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence
A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.
- Glutathione: the master antioxidant, and where the evidence actually is
Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.
- What the semaglutide weight-loss trials actually showed
STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.
- Tirzepatide vs semaglutide for weight loss: what the trials actually support
Most comparisons are cross-trial. Only SURPASS-2 and SURMOUNT-5 randomized one drug against the other — here's the precise distinction.
How Trellis Vitality compares
A few alternatives worth a look, depending on what you’re optimizing for.
the edit.Buyers who want the practice, pharmacy and management company all named before they pay
See the edit. →
AurenRxBuyers who want a named pharmacy and will read past the advertised headline price
See AurenRx →
PeptiBuyers who want the widest set of GLP-1 routes with a price published against each
See Pepti →
Access & cost · Reviewed and last verified August 2026
How we assessed this. This review reflects Aminoscope’s own read of Trellis Vitality’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- How much does Trellis charge for NAD+?
- It does not say. We checked the NAD+ product page, the intake funnel and every other page on the site, and found no published figure for the NAD+ protocol. The only price on that page is what a clinic infusion costs elsewhere ($200–500). You will need to ask Trellis directly or begin the free assessment.
- What does Trellis's GLP-1 line cost?
- Semaglutide is $150/mo month-to-month, $140/mo on a three-month plan and $133/mo on six. Tirzepatide is $199, $189 and $179 on the same terms. Notably, the price is the same at every dosage, so it does not rise as your clinician titrates you up.
- Is the "92% of patients" figure backed by anything?
- Not that Trellis publishes. The claim appears on the homepage as "92% of patients see significant biomarker improvements within 90 days," annotated only as "confirmed on your 90-day re-test, not self-reported." No study, sample size, time period or methodology is given, and we found no supporting document anywhere on the site.
- Who fills a Trellis prescription?
- VialsRX, a state-licensed compounding pharmacy in Houston, Texas. The prescribing group is Arora Health & Aesthetics, LLC, with Dr. Sean Arora as medical director. Both are named in Trellis's own llms.txt.
- Does injected NAD+ have evidence behind it?
- Not for clinical outcomes. No controlled human outcome trial supports injected or intranasal NAD+. The randomized evidence in this area belongs to the oral precursors NR and NMN, and even there the demonstrated result is a raised blood NAD+ level rather than a proven health benefit.